

KURZPROTOKOLL PSOHO

Öffentlicher Titel	Beobachtungsstudie bei moderater bis schwerer Schuppenflechte
Wissenschaftl. Titel	Psoriasis Study of Health Outcomes (PSOHO) an International Observational Study of 3-year Health Outcomes in Biologic Treatment of Moderate-to Severe Plaque Psoriasis
Kurztitel	PSOHO
Studienart	multizentrisch, prospektiv, offen/unverblindet, Pharma-Studie, nicht-interventionelle Studie
Studienphase	nicht zutreffend
Erkrankung	Haut: Schuppenflechte (Psoriasis)
Einschlusskriterien	<ul style="list-style-type: none">- Adult male and female patients (≥ 18 and ≤ 80 and in accordance with country-specific requirements) who present within the usual course of care- A diagnosis of moderate-to-severe plaque-type psoriasis for at least 6 months prior to baseline, as determined by the investigator- First-time treatment with a biologic or switch to a new biologic agent (including biosimilars) according to country-specific approved indication- Able to provide written informed consent as approved by Eli Lilly and Company (Lilly) or its designee, and the Investigational Review Board/ethical review board (ERB) governing the site and/or study
Ausschlusskriterien	<ul style="list-style-type: none">- Treatment initiation contraindicated due to country-specific approved indication- Dose changes or changes in dosing intervals of an existing biologic treatment- Restart of treatment with a biologic previously received at any time during the patient's treatment history- Completion or withdrawal from this study- Current participation in any other psoriasis study with any investigational products
Alter	18 - 80 Jahre
Sponsor	Eli Lilly and Company